AlloVir, Inc. (ALVR)
$
9.81
+0.39 (3.98%)
Key metrics
Financial statements
Free cash flow per share
-2.9513
Market cap
48.1 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
14.3072
Income quality
0.8794
Average inventory
0
ROE
1.0667
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Allovir, Inc. is a clinical-stage cell therapy company focused on the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating severe viral-associated diseases. The company's lead product, posoleucel, is designed to combat viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. In addition to posoleucel, Allovir's portfolio includes several preclinical and clinical product candidates: ALVR106 targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 is focused on treating SARS-CoV-2 and COVID-19; ALVR107 is aimed at hepatitis B; while ALVR108 is also under development. The company earned an interest income of $5,486,000.00 showcasing its financial investments. The income before tax ratio is $0.00 reflecting the pre-tax margin. Additionally, the gross profit stands at $0.00 highlighting the company's profitability from core operations. However, it reported a net loss of -$58,769,000.00 indicating challenges in its operations. The diluted EPS is -$11.73 accounting for potential share dilution. In the financial market, Allovir's stock is affordable at $9.81 making it appealing to budget-conscious investors. The stock has a low average trading volume of 22,940.00 indicating lower market activity and possibly less liquidity. With a market capitalization of $49,475,362.00 the company is classified as a small-cap player, which often entails higher volatility but also potential growth. Allovir is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, especially in the fight against viral diseases. As it belongs to the Healthcare sector, Allovir drives innovation and growth, positioning itself strategically within the rapidly evolving field of cell therapies and antiviral treatments.
What is AlloVir, Inc. (ALVR)'s stock forecast?
Analysts predict AlloVir, Inc. stock to fluctuate between $7.96 (low) and $24.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is AlloVir, Inc.'s market capitalization?
As of 2025-03-18, AlloVir, Inc.'s market cap is $49,475,362, based on 5,043,360 outstanding shares.
How does AlloVir, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, AlloVir, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy AlloVir, Inc. (ALVR) stock?
To buy AlloVir, Inc. (ALVR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALVR. Place an order (Market, Limit, etc.).
What is the best time to invest in AlloVir, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has AlloVir, Inc. stock ever split?
AlloVir, Inc.'s last stock split was 1:23 on 2025-01-16.
How did AlloVir, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$11.73 | Growth: -72.13%.
Where can I find AlloVir, Inc.'s investor relations reports?
Visit https://www.allovir.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for AlloVir, Inc.?
You can explore historical data from here
What is the all-time high and low for AlloVir, Inc. stock?
All-time high: $607.43 (2021-10-01) | All-time low: $7.96 (2025-01-16).
What are the key trends affecting AlloVir, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
14 days ago
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In AlloVir (ALVR) To Contact Him Directly To Discuss Their Options
accessnewswire.com
2 months ago
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
accessnewswire.com
2 months ago
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
accessnewswire.com
2 months ago
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
accessnewswire.com
2 months ago
NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
accessnewswire.com
3 months ago
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
globenewswire.com
3 months ago
BOSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of AlloVir, Inc. securities (NASDAQ: KLRS):
accessnewswire.com
3 months ago
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
accessnewswire.com
3 months ago
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.
globenewswire.com
5 months ago
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina
See all news
